| 000 | 01400 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250516123654.0 | ||
| 264 | 0 | _c20140114 | |
| 008 | 201401s 0 0 eng d | ||
| 022 | _a1365-2710 | ||
| 024 | 7 |
_a10.1111/jcpt.12031 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAsaithambi, G | |
| 245 | 0 | 0 |
_aPosterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. _h[electronic resource] |
| 260 |
_bJournal of clinical pharmacy and therapeutics _cApr 2013 |
||
| 300 |
_a175-6 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aIndazoles |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPosterior Leukoencephalopathy Syndrome _xchemically induced |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 |
_aSulfonamides _xadverse effects |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 700 | 1 | _aPeters, B R | |
| 700 | 1 | _aHurliman, E | |
| 700 | 1 | _aMoran, B P | |
| 700 | 1 | _aKhan, A S | |
| 700 | 1 | _aTaylor, R A | |
| 773 | 0 |
_tJournal of clinical pharmacy and therapeutics _gvol. 38 _gno. 2 _gp. 175-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/jcpt.12031 _zAvailable from publisher's website |
| 999 |
_c22318898 _d22318898 |
||